Trials / Conditions / Nonsquamous Nonsmall Cell Neoplasm of Lung

Nonsquamous Nonsmall Cell Neoplasm of Lung

13 registered clinical trials studyying Nonsquamous Nonsmall Cell Neoplasm of Lung — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy NCT05764928	Rgene Corporation	Phase 1 / Phase 2
Completed	A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer NCT03846310	Arcus Biosciences, Inc.	Phase 1
Completed	A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NCT03380871	BioNTech US Inc.	Phase 1
Terminated	Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Me NCT02831933	Eric Bernicker, MD	Phase 2
Unknown	Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC NCT02852798	Jiangsu ShengDiYa Medicine Co., Ltd.	—
Completed	Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy NCT02679443	Post Graduate Institute of Medical Education and Research, Chandigarh	N/A
Completed	A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of De NCT02259582	OncoMed Pharmaceuticals, Inc.	Phase 2
Terminated	Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Smal NCT02019979	Beth Israel Medical Center	Phase 2
Completed	Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin NCT02049060	Armando Santoro, MD	Phase 1 / Phase 2
Completed	Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung NCT01705184	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
Terminated	Cisplatin and Pemetrexed With Radiation Followed by Lobectomy NCT01373463	Medical University of South Carolina	Phase 1
Completed	Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab NCT01814163	Spanish Lung Cancer Group	—
Completed	An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in P NCT01161173	Hoffmann-La Roche	—